Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZXRLG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
sLV-154
|
|||||
| Synonyms |
SLV-154
Click to Show/Hide
|
|||||
| Organization |
Solve Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Sarcomas |
1 Trials
|
||||||||
| Thyroid cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|